Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis
This article conducts a meta-analysis to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). A total of 63 papers were initially retrieved, and eight clinical studies were collected. The estimated effect of ORR was...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2025-08-01
|
| Series: | Open Life Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/biol-2025-1129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390225952866304 |
|---|---|
| author | Zhang Jiawen Xu Lei Sun Caifeng Huang Zonghua Ma Ji Wang Liang |
| author_facet | Zhang Jiawen Xu Lei Sun Caifeng Huang Zonghua Ma Ji Wang Liang |
| author_sort | Zhang Jiawen |
| collection | DOAJ |
| description | This article conducts a meta-analysis to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). A total of 63 papers were initially retrieved, and eight clinical studies were collected. The estimated effect of ORR was [OR = 0.40, 95% CI 0.29–0.51; p = 0.08], the estimated effect of complete response rate was [OR = 0.21, 95% CI 0.14–0.31; p < 0.001], while the estimated effect of 1-year progression-free survival was [OR = 0.33, 95% CI 0.22–0.47; p = 0.01]. The estimated effect of 1-year OS was [OR = 0.67, 95% CI 0.55–0.77; p = 0.05]. In addition, the estimated effect of grade 3 adverse events was [OR = 0.33, 95% CI 0.22–0.46; p = 0.01]. Overall, PD-1/PD-L1 inhibitors demonstrated suboptimal therapeutic efficacy in the selected trials for R/R DLBCL. However, combining PD-1/PD-L1 inhibitors with CAR-T showed potential for improved treatment outcomes. Additionally, PD-1/PD-L1 inhibitors were found to be safe and well-tolerated in patients with R/R DLBCL. |
| format | Article |
| id | doaj-art-d248010c29f04db186acb14f8e4ff6de |
| institution | Kabale University |
| issn | 2391-5412 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Life Sciences |
| spelling | doaj-art-d248010c29f04db186acb14f8e4ff6de2025-08-20T03:41:43ZengDe GruyterOpen Life Sciences2391-54122025-08-012012162110.1515/biol-2025-1129Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysisZhang Jiawen0Xu Lei1Sun Caifeng2Huang Zonghua3Ma Ji4Wang Liang5Clinical Medicine School, Shandong Second Medical University, No. 4948, Victory East Street, Weifang, Shandong, 261000, ChinaDepartment of Medical Imaging, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying District, Dongying, Shandong, 257034, ChinaDepartment of Hematology, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying District, Dongying, Shandong, 257034, ChinaDepartment of Hematology, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying District, Dongying, Shandong, 257034, ChinaDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong, Academy of Medical Sciences, No. 440, Jiyan Highway, Huaiyin District, Jinan, Shandong, 250117, ChinaDepartment of Hematology, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying District, Dongying, Shandong, 257034, ChinaThis article conducts a meta-analysis to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). A total of 63 papers were initially retrieved, and eight clinical studies were collected. The estimated effect of ORR was [OR = 0.40, 95% CI 0.29–0.51; p = 0.08], the estimated effect of complete response rate was [OR = 0.21, 95% CI 0.14–0.31; p < 0.001], while the estimated effect of 1-year progression-free survival was [OR = 0.33, 95% CI 0.22–0.47; p = 0.01]. The estimated effect of 1-year OS was [OR = 0.67, 95% CI 0.55–0.77; p = 0.05]. In addition, the estimated effect of grade 3 adverse events was [OR = 0.33, 95% CI 0.22–0.46; p = 0.01]. Overall, PD-1/PD-L1 inhibitors demonstrated suboptimal therapeutic efficacy in the selected trials for R/R DLBCL. However, combining PD-1/PD-L1 inhibitors with CAR-T showed potential for improved treatment outcomes. Additionally, PD-1/PD-L1 inhibitors were found to be safe and well-tolerated in patients with R/R DLBCL.https://doi.org/10.1515/biol-2025-1129pd-1/pd-l1 blockadeimmune checkpoint moleculerelapsed/refractory diffuse large b-cell lymphomatreatmentmeta-analysis |
| spellingShingle | Zhang Jiawen Xu Lei Sun Caifeng Huang Zonghua Ma Ji Wang Liang Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis Open Life Sciences pd-1/pd-l1 blockade immune checkpoint molecule relapsed/refractory diffuse large b-cell lymphoma treatment meta-analysis |
| title | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis |
| title_full | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis |
| title_fullStr | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis |
| title_full_unstemmed | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis |
| title_short | Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis |
| title_sort | efficacy and safety of anti pd 1 pd l1 antibodies in patients with relapsed refractory diffuse large b cell lymphoma a meta analysis |
| topic | pd-1/pd-l1 blockade immune checkpoint molecule relapsed/refractory diffuse large b-cell lymphoma treatment meta-analysis |
| url | https://doi.org/10.1515/biol-2025-1129 |
| work_keys_str_mv | AT zhangjiawen efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis AT xulei efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis AT suncaifeng efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis AT huangzonghua efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis AT maji efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis AT wangliang efficacyandsafetyofantipd1pdl1antibodiesinpatientswithrelapsedrefractorydiffuselargebcelllymphomaametaanalysis |